Table 2: Summary of WHO Position Papers - Recommended Routine Immunizations for Children

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Age of 1st Dose</th>
<th>Doses in Primary Series</th>
<th>Interval Between Doses</th>
<th>Booster Dose</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>1st to 2nd</td>
<td>2nd to 3rd</td>
<td>3rd to 4th</td>
</tr>
<tr>
<td>BCG 1</td>
<td>As soon as possible after birth</td>
<td>1</td>
<td>4 weeks (min)</td>
<td>4 weeks (min)</td>
<td>4 weeks (min), with DTP3</td>
</tr>
<tr>
<td>Hepatitis B 2</td>
<td>Option 1: As soon as possible after birth (&lt;24h)</td>
<td>3</td>
<td>4 weeks (min) with DTP1</td>
<td>4 weeks (min) with DTP3</td>
<td>4 weeks (min), with DTP3</td>
</tr>
<tr>
<td></td>
<td>Option 2: As soon as possible after birth (&lt;24h)</td>
<td>4</td>
<td>4 weeks (min) with DTP1</td>
<td>4 weeks (min) with DTP3</td>
<td>4 weeks (min), with DTP3</td>
</tr>
<tr>
<td>Polio 3</td>
<td>bOPV + IPV: 6 weeks (see footnote for birth dose)</td>
<td>4</td>
<td>4 weeks (min) with DTP2</td>
<td>4 weeks (min) with DTP3</td>
<td>(see footnote)</td>
</tr>
<tr>
<td></td>
<td>IPV / bOPV Sequential: 8 weeks (IPV 1st)</td>
<td>1-2 IPV 2 bOPV</td>
<td>4-8 weeks</td>
<td>4-8 weeks</td>
<td>4-8 weeks</td>
</tr>
<tr>
<td></td>
<td>IPV: 8 weeks</td>
<td>3</td>
<td>4-8 weeks</td>
<td>4-8 weeks</td>
<td>(see footnote)</td>
</tr>
<tr>
<td></td>
<td>DTP-containing vaccine 4: 6 weeks (min)</td>
<td>3</td>
<td>4 weeks (min) - 8 weeks</td>
<td>4 weeks (min) - 8 weeks</td>
<td>3 Boosters 12-23 months (DTP-containing vaccine); 4-7 years (Td); and 9-15 yrs (Td)</td>
</tr>
<tr>
<td>Haemophilus influenzae type b 5</td>
<td>Option 1: 6 weeks (min) 59 months (max)</td>
<td>3</td>
<td>4 weeks (min) with DTP2</td>
<td>4 weeks (min) with DTP3</td>
<td>(see footnote)</td>
</tr>
<tr>
<td></td>
<td>Option 2: 2-3 8 weeks (min) if only 2 doses 4 weeks (min) if 3 doses</td>
<td>2</td>
<td>4 weeks (min) if 3 doses</td>
<td>4 weeks (min) if 3 doses</td>
<td>At least 6 months (min) after last dose</td>
</tr>
<tr>
<td>Pneumococcal (Conjugate) 6</td>
<td>Option 1: 6 weeks (min)</td>
<td>3</td>
<td>4 weeks (min)</td>
<td>4 weeks</td>
<td>(see footnote)</td>
</tr>
<tr>
<td></td>
<td>Option 2: 6 weeks (min)</td>
<td>2</td>
<td>8 weeks (min)</td>
<td></td>
<td>9-15 months</td>
</tr>
<tr>
<td>Rotavirus 7</td>
<td>Rotarix: 6 weeks (min) with DTP1</td>
<td>2</td>
<td>4 weeks (min) with DTP2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rota Teq: 6 weeks (min) with DTP1</td>
<td>3</td>
<td>4 weeks (min) - 10 weeks with DTP2</td>
<td>4 weeks (min) with DTP3</td>
<td></td>
</tr>
<tr>
<td>Measles 8</td>
<td>9 or 12 months (6 months min, see footnote)</td>
<td>2</td>
<td>4 weeks (min)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rubella 9</td>
<td>9 or 12 months with measles containing vaccine</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV 10</td>
<td>As soon as possible from 9 years of age (females only)</td>
<td>2</td>
<td>6 months (min 5 months)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Refer to: http://www.who.int/immunization/documents/positionpapers/ for table & position paper updates.

This table summarizes the WHO vaccination recommendations for children. The ages/intervals cited are for the development of country specific schedules and are not for health workers. National schedules should be based on local epidemiologic, programmatic, resource & policy considerations. While vaccines are universally recommended, some children may have contraindications to particular vaccines.
### Table 2: Summary of WHO Position Papers - Recommended Routine Immunizations for Children (updated March 2017)

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Age of 1st Dose</th>
<th>Doses in Primary Series</th>
<th>Interval Between Doses</th>
<th>Booster Dose</th>
<th>Considerations (see footnotes for details)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendations for children residing in certain regions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japanese Encephalitis 11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated Vero cell-derived</td>
<td>6 months</td>
<td>2 generally</td>
<td>4 weeks (generally)</td>
<td></td>
<td>Vaccine options and manufacturer's recommendations; Pregnancy; Immunocompromised</td>
</tr>
<tr>
<td>Live attenuated</td>
<td>8 months</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Live recombinant</td>
<td>9 months</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yellow Fever 12</td>
<td>9-12 months with measles containing vaccine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tick-Borne Encephalitis 13</td>
<td>≥1 yr FSME-Immun and Encepur</td>
<td>3</td>
<td>1-3 months FSME-Immun and Encepur</td>
<td></td>
<td>At least 1 Every 3 years (see notes)</td>
</tr>
<tr>
<td></td>
<td>≥3 yrs TBE_Moscow and EnceVir</td>
<td></td>
<td>1-7 months TBE-Moscow and EnceVir</td>
<td></td>
<td>Definition of high-risk Vaccine options Timing of booster</td>
</tr>
</tbody>
</table>

| **Recommendations for children in some high-risk populations**             |                 |                         |             |                                          |                                             |
| Typhoid 14                    |                 |                         |             |                                          |                                             |
| Vi PS                         | 2 years (min)   | 1                       | 1 day       | 1 day         | 1 day | Every 3 years | Definition of high risk |
| Ty21a                         | Capsules 5 years (min) (see footnote) | 3 or 4 (see footnote) |             |              |              |              |                                             |
|                               | 1 year (min)    | 2                       | 14 days     |              |              |              |                                             |
| Cholera 15                    |                 |                         |             |                                          |                                             |
| Dukoral (WC-rBS)              | 2 years (min)   | 3 (2-5 years)           | ≥7 days (min) < 6 weeks (max) |              |              | Every 6 months | Definition of high risk |
|                               | 1 year (min)    | 2                       | ≥7 days (min) < 6 weeks (max) |              |              | Every 2 years | Minimum age Definition of high risk |
|                               | Shanchol and mORCVAX |                        | 1-3 months TBE-Moscow and EnceVir |              |              |              |                                             |
| Meningococcal 16              |                 |                         |             |                                          |                                             |
| MenA conjugate                | 9-18 months (5µg) | 1                       |             |              |              |              |                                             |
| MenC conjugate                | 2-11 months     | 2                       | 8 weeks     |              |              | After 1 year | Definition of high risk Vaccine options |
|                               | ≥12 months      | 1                       |             |              |              |              |                                             |
| Quadrivalent conjugate        | 9-23 months     | 2                       | 12 weeks    |              |              |              |                                             |
|                               | ≥2 years        | 1                       |             |              |              |              |                                             |
| Hepatitis A 17                | 1 year          | At least 1              |             |              |              |              | Level of endemicity; Vaccine options; Definition of high risk groups |
| Rabies 18                     | As required     | 3                       | 7 days      | 14-21 days (see footnote) |              |              | Definition of high risk, booster |
| Dengue (CYD-TDV) 19           | 9 years (min)   | 3                       | 6 months    | 6 months     |              |              | Seroprevalence |

| **Recommendations for children receiving vaccinations from immunization programmes with certain characteristics** |
|                                                             |                 |                         |             |                                          |                                             |
| Mumps 20                                                     | 12-18 months with measles containing vaccine | 2                        | 1 month (min) to school entry |              | Coverage criteria > 80%; Combo vaccine |
| Seasonal influenza (inactivated tri- and quadri-valent) 21  | 6 months (min)  | 2 (<9 years)            | 4 weeks     |              | Revaccinate annually; 1 dose only (see footnotes) Priority risk groups, especially pregnant women Lower dosage for children 6-35 months |
|                                                             | 1 (≥9 years)    | 1                       |             |              |                                             |
| Varicella 22                                                 | 12-18 months    | 1-2                     | 4 weeks to 3 months per manufacturer recommendations |              | Achieve & sustain ≥80% coverage Pregnancy Co-admin with other live vaccines |
### Table 2: Recommended Routine Immunization for Children (updated March 2017)

#### 1. BCG
- Recommended for children living in countries with a high-disease burden and for high-risk children living in countries with low-disease burden. See position paper for details.
- While BCG vaccination is especially important in countries with significant HIV prevalence, children who are HIV positive or unknown HIV status with symptoms consistent with HIV should not be vaccinated. Reference: [Weekly Epid. Record (2007, 82: 193-196)](http://www.who.int/immunization/documents/immunological_basis_series/en/index.html [pdf 167kb])

#### 2. Hepatitis B
- Since perinatal or early postnatal transmission is an important cause of chronic infections globally, all infants should receive their first dose of hepatitis B vaccine as soon as possible (<24 hours) after birth even in low-endemicity countries.
- The primary hepatitis B immunization series conventionally consists of 3 doses of vaccine (1 monovalent birth dose followed by 2 monovalent or combined vaccine doses at the time of DTP1 and DTP3 vaccine doses). However, 4 doses may be given for programmatic reasons (e.g. monovalent birth-dose followed by 3 monovalent or combined vaccine doses with DTP vaccine doses), according to the schedules of national routine immunization programmes.
- Premature low birth weight (<2000g) may not respond well to vaccination at birth. However, by 1 month of chronological age, premature infants, regardless of their initial weight or gestational age at birth, are likely to respond adequately. Therefore, doses given to infants <2000g should not be counted towards the primary series.

#### 3. Polio

### OPV plus IPV
- For all countries using OPV in the national immunization programme, WHO recommends the inclusion of at least one dose of IPV in the vaccination schedule.
- In polio-endemic countries and in countries at high risk for importation and subsequent spread of poliovirus, WHO recommends a bOPV birth dose (zero dose) followed by a primary series of 3 bOPV doses and at least 1 IPV dose.
- The zero dose of bOPV should be administered at birth, or as soon as possible after birth, to maximize seroconversion rates following subsequent doses and to induce mucosal protection.
- The primary series consisting of 3 bOPV doses plus 1 IPV dose can be initiated from the age of 6 weeks with a minimum interval of 4 weeks between the bOPV doses. If 1 dose of IPV is used, it should be given at 14 weeks of age or later (when maternal antibodies have diminished and immunogenicity is significantly higher) and can be co-administered with a bOPV dose.
- The primary series can be administered according to the regular schedules of national immunization programmes, e.g. at 6, 10, and 14 weeks (bOPV, bOPV, bOPV+IPV), or at 2, 4, and 6 months (bOPV, bOPV+IPV, bOPV or bOPV, bOPV, bOPV+IPV).
- Both OPV and IPV may be co-administered with other infant vaccines.
- For infants starting the routine immunization schedule late (age >3 months) the IPV dose should be administered at the first immunization contact along with bOPV and the other routinely recommended vaccines.
- As an alternative to the intramuscular injection of a full dose of IPV, countries may consider using fractional doses (1/5 of the full IPV dose) via the intradermal route, but the programmatic cost and logistic implications of this option should be considered.
- To ensure early protection a schedule of fractional intradermal doses administered at 6 and 14 weeks may be considered. The 2 fractional doses should be separated by a minimum interval of 4 weeks.
- The implementation of the new infant schedule (3 bOPV doses + 1 IPV dose) does not replace the need for supplementary immunization activities (SIAs). Those countries with insufficient routine vaccination coverage and which rely on SIAs to increase population immunity should continue the SIAs using bOPV until routine coverage improves or until the globally-coordinated withdrawal of bOPV.

### Sequential IPV–OPV schedule
- **In countries with high vaccination coverage (e.g. 90%-95%) and low importation risk (neighbouring countries and major population movement all having similarly high coverage) an IPV–bOPV sequential schedule can be used when VAPP is a significant concern.**
- The initial administration of 1 or 2 doses of IPV should be followed by ≥2 doses of bOPV to ensure both sufficient levels of protection in the intestinal mucosa and a decrease in the burden of VAPP.
- For sequential IPV–bOPV schedules, WHO recommends that IPV be given at 2 months of age (e.g. a 3-dose IPV–bOPV–bOPV schedule), or at 2 months and 3–4 months of age (e.g. a 4-dose IPV–IPV–OPV–OPV schedule) followed by at least 2 doses of bOPV. Each of the doses...
in the primary series should be separated by 4–8 weeks depending on the risk of exposure to poliovirus in early childhood.

**IPV-only schedule**

- An IPV-only schedule may be considered in countries with sustained high vaccination coverage and very low risk of both WPV importation and transmission.
- A primary series of 3 doses of IPV should be administered beginning at 2 months of age. If the primary series begins earlier (e.g. with a 6, 10 and 14-week schedule) then a booster dose should be given after an interval of ≥6 months (for a 4-dose schedule).

**DTP-containing vaccine (Diphtheria, Tetanus and Pertussis)**

- Recommended for three doses during the first year of life. In areas where pertussis is of particular risk to young infants, DTP should be started at 6 weeks with 2 subsequent doses at intervals of 4-8 weeks each. The last dose of the primary series should be completed by the age of 6 months.
- The duration of immunological protection will be extended in many instances if an additional booster is given later. A pertussis booster - to compensate for the loss of natural diphtheria boosting in some areas, childhood boosters should be given. The optimal timing of and number of diphtheria-containing booster doses should be based on epidemiological surveillance as well as on immunological and programmatic considerations.
- Tetanus - To ensure lifelong protection against tetanus in all people should receive 6 doses (3 primary plus 3 booster doses) of tetanus toxoid-containing vaccine (TTCV) through routine childhood immunization schedules.
- The 3 TTCV booster doses should be given at: 12–23 months of age; 4–7 years of age; and 9–15 years of age. Ideally, there should be at least 4 years between booster doses.
- National vaccination schedules can be adjusted within the age limits specified above to enable programmes to tailor their schedules based on local epidemiology, the objectives of the immunization programme, any particular programmatic issues and to better align tetanus vaccination with the immunological requirements of other vaccines (particularly for pertussis and diphtheria).
- Opportunities for tetanus vaccination may be taken at the second year of life contacts for alternative PCV schedule 2 + 1, MCV second dose, and meningococcal A-containing vaccines, as well as pre-adolescence and adolescence contacts including for HPV vaccination.
- To provide and sustain both tetanus and diphtheria immunity throughout the life course and for both sexes, age-appropriate combinations of tetanus and diphtheria toxoids should be used. For children <7 years of age DTwP or DTAP combinations may be used. For children aged 4 years and older Td may be used and is preferred.
- From 7 years of age only Td combinations should be used. Age-appropriate combinations containing pertussis vaccine with low-dose diphtheria antigen are also available.
- If tetanus vaccination is started during adolescence or adulthood, a total of only 5 appropriately spaced doses are required to obtain lifelong protection.
- Pregnant women and their newborn infants are protected from birth-associated tetanus if the mother received either 6 TTCV doses during childhood or 5 doses if first vaccinated during adolescence/adulthood (documented by card, immunization registry and/or history) before the time of reproductive age. Vaccination history should be verified in order to determine whether a dose of TTCV is needed in the current pregnancy.

**Pertussis vaccine**

- Both aP-containing and wP-containing vaccines have excellent safety records.
- Available evidence indicates that licensed aP and wP vaccines have equivalent initial effectiveness in preventing disease in the first year of life, but that there is more rapid waning of immunity, and possibly a reduced impact on transmission, with aP relative to wP vaccines.
- National programmes currently administering wP vaccination should continue to use wP vaccines for primary vaccination series. Surveillance and modelling data suggest that the use of aP vaccines may result in a resurgence of pertussis after a number of years.
- National programmes currently using aP vaccine may continue using this vaccine but should consider the need for additional booster doses and strategies to prevent early childhood mortality such as maternal immunization in case of resurgence of pertussis.
- Only aP-containing vaccines should be used for vaccination of persons aged ≥7 years.
- Pertussis containing booster - A booster dose is recommended for children aged 1–6 years, preferably during the second year of life (≥6 months after last primary dose), unless otherwise indicated by local epidemiology; the contact could also be used to catch up on any missed doses.
- National programmes may consider the vaccination of pregnant women with 1 dose of Tdap (in the 2nd or 3rd trimester and preferably at least 15 days before the end of pregnancy) as a strategy additional to routine primary infant pertussis vaccination in countries or settings with high or increasing infant morbidity/ mortality from pertussis.
- Delayed or interrupted DTP series - For children whose vaccination series has been interrupted, the series should be resumed without repeating previous doses. Children aged 1 to < 7 years who have not previously been vaccinated should receive 3 doses of vaccine.
- Health-care workers should be prioritized as a group to receive pertussis vaccine.

**Haemophilus influenzae type b (Hib)**

- The use of Hib vaccines should be part of a comprehensive strategy to control pneumonia including exclusive breastfeeding for six months, hand washing with soap, improved water supply and sanitation, reduction of household air pollution, and improved case management at community and health facility levels.
- WHO recommends that any one of the following Hib immunization schedules may be followed: 3 primary doses without a booster (3p); 2 primary doses plus a booster (2p+1); and 3 primary doses with a booster (3p+1).
- Because serious Hib disease occurs most commonly in children aged between 4 months and 18 months, immunization should start from 6 weeks of age, or as early as possible thereafter.
- The number of primary doses should be set after consideration of the local epidemiology, vaccine
presentation (Hib conjugate monovalent vaccine versus Hib conjugate vaccine in combination with other antigens) and how this fits into the overall routine immunization schedule.

- In countries where the peak burden of severe Hib disease occurs in young infants, providing 3 doses of vaccine early in life may confer a greater benefit.
- In some settings (e.g. where the greatest disease morbidity and mortality occur later, or where rate reductions of disease are not fully sustained after the routine use of Hib vaccine), it might be advantageous to give a booster dose by following either a 2p+1 or 3p+1 schedule.

- The interval between doses should be at least 4 weeks if 3 primary doses are given, and at least 8 weeks if 2 primary doses are given. Booster doses should be administered at least six months after completion of the primary series.
- If the vaccination course has been interrupted, the schedule should be resumed without repeating the previous dose. Children who start vaccination late, but are aged under 12 months, should complete the vaccination schedule (e.g. have 3 primary doses or 2 primary doses plus a booster).
- When a first dose is given to a child older than 12 months of age, only one dose is recommended.
- Hib vaccine is not required for healthy children after 5 years of age.
- The Hib conjugate vaccine is contraindicated in people with known allergies to any component of the vaccine. There are no other known contraindications or precautions.

6 Pneumococcal (Conjugate)


Pneumococcal conjugate vaccines (PCVs) are considered safe in all target groups for vaccination, also in immunocompromised individuals. The vaccines are not currently licensed for use in age groups that include women of childbearing age. Although theoretically highly unlikely to be harmful, there is no information on the safety of PCV10 and PCV13 during pregnancy.

- Except for very rare anaphylactic reactions that may follow the administration of any medicine, there are no contraindications to the use of these vaccines. However, it is advisable to defer vaccination until after an acute infection with temperature >39 °C.

- When injected at different sites, PCVs can be administered concurrently with any other vaccines in infant immunization programmes.

- When primary immunization is initiated with one of these vaccines, it is recommended that remaining doses are administered with the same product. Interchangeability between PCV10 and PCV13 has not yet been documented. However, if it is not possible to complete the series with the same type of vaccine, the other PCV product should be used.

- For infants, 3 primary doses (the 3p+0 schedule) or, as an alternative, 2 primary doses plus a booster (the 2p+1 schedule).

- In choosing between the 3p+0 and 2p+1 schedules, countries should consider locally relevant factors including the epidemiology of pneumococcal disease, the likely coverage, and the timeliness of the vaccine doses.

- If disease incidence peaks in young infants (<32 weeks of age), a 2p+1 schedule might not offer optimal individual protection for certain serotypes (e.g. 6B, 23F) compared to a 3p+0 schedule, particularly in the absence of herd protection.

- In contrast, higher antibody levels are induced by the third (booster) dose in a 2p+1 schedule compared to the third dose in a 3p+0 schedule. This may be important for duration of protection or effectiveness against some serotypes.

- If the 3p+0 schedule is used, vaccination can be initiated as early as 6 weeks of age with an interval between doses of 4–8 weeks, depending on programmatic convenience.

- If the 2p+1 schedule is selected, the 2 primary doses should ideally be completed by six months of age, starting as early as 6 weeks of age with a minimum interval of 8 weeks or more between the two doses (for infants aged ≥7 months a minimum interval of 4 weeks between doses is possible). One booster dose should be given between 9–15 months of age.

- Previously unvaccinated or incompletely vaccinated children (including those who had laboratory confirmed invasive pneumococcal disease) should be vaccinated using the recommended age-appropriate regimens. Interrupted schedules should be resumed without repeating the previous dose.

- HIV-positive infants and pre-term neonates who have received their 3 primary vaccine doses before reaching 12 months of age may benefit from a booster dose in the second year of life.

- Catch-up vaccination as part of introduction will accelerate herd protection and therefore the PCV impact on disease and carriage. Maximized protection at the time of introduction of PCV10 or PCV13 can be achieved by providing 2 catch-up dose(s) at an interval of at least 8 weeks to unvaccinated children aged 12–24 months and to children aged 2–5 years who are at high risk of pneumococcal infection.

- Further data are needed from different epidemiological settings on the impact of large-scale PCV vaccination of individuals >50 years of age in order to establish the relative priority of immunization programmes in that age group. However, given the documented effects of herd protection in adult age groups following routine infant immunization with PCV7, higher priority should normally be given to introducing and maintaining high coverage of infants with PCVs.

- The use of pneumococcal vaccine should be seen as complementary to the use of other pneumonia control measures, such as appropriate case management, promotion of exclusive breastfeeding for first 6 months of life, and the reduction of known risk factors, such as indoor pollutants and tobacco smoke.

- For polysaccharide pneumococcal vaccine see position paper: Weekly Epid. Record (2008, 83: 373-384) [pdf 308kb]

- In resource-limited settings where there are many competing health priorities, evidence does not support routine immunization of the elderly and high-risk populations with PPV23. Also, because of the low level of evidence for benefit, routine PPV23 vaccination of HIV-infected adults is not recommended in such settings. In countries that do not routinely administer PPV23 to high-risk populations, data are insufficient to recommend introducing this vaccine to reduce the morbidity and mortality associated with influenza.

7 Rotavirus


- Recommended to be included in all national immunization programmes.

- Early immunization is favoured with the first dose of rotavirus vaccine to be administered from 6 weeks of age, however, in order to benefit those who may come late in life can receive doses without age restriction. Because of the typical age distribution of rotavirus gastroenteritis (RVGE), rotavirus vaccination of children >24 months of age is not recommended.

- Rotarix is administered orally in a 2-dose schedule at the time of DTP1/penta and DTP2/penta with an interval of at least 4 weeks between doses.

- RotaTeq vaccine is administered orally in a 3-dose schedule at the time of DTP1/penta, DTP2, and DTP3 contacts, with an interval of at least 4 weeks between doses.

- Rotavirus vaccinations can be administered simultaneously with other vaccines in the infant immunization programme.

- Apart from a low risk of intussusception (about 1-2 per 100 000 infants vaccinated) the current rotavirus vaccines are considered safe and well tolerated.

- Severe allergic reaction (e.g. anaphylaxis) after a previous dose, and severe immunodeficiency

Table 2: Recommended Routine Immunization for Children (updated March 2017)
# Table 2: Recommended Routine Immunization for Children (updated March 2017)

## 8 Measles


- Reaching all children with 2 doses of measles vaccine should be the standard for all national immunization programmes. In addition to the first routine dose of MCV1, all countries should add a second routine dose of MCV2 to their national immunization schedules regardless of the level of MCV1 coverage.

- Because many cases of measles occur in children aged >12 months who have not been vaccinated, routine delivery of MCV1 should not be limited to infants aged 9–12 months and routine delivery of MCV2 should not be limited to infants 15 to 18 months of age. Every opportunity (e.g. when children come into contact with health services) should be taken to vaccinate all unvaccinated children that missed one or both MCV routine doses, particularly those under 15 years of age. Policies which prohibit use of vaccine in children >1 year of age, older children and teenagers should be changed to allow these individuals to be vaccinated.

- In countries with ongoing transmission in which the risk of measles mortality remains high, MCV1 should be given at age 9 months. MCV2 should be given between 15-18 months, as providing MCV2 in the 2nd year of life reduces the rate of accumulation of susceptible children and the risk of an outbreak.

- In countries with low rates of measles transmission (that is, those that are near elimination) and where there is a low risk of measles infection among infants, the first dose may be administered at age 12 months to take advantage of the higher seroconversion rates achieved at this age (>90% seroconversion). In these countries the optimal age for delivering a routine 2nd dose of measles is based on programmatic considerations that achieve the highest coverage and hence the highest population immunity. Administration of the second dose at age 15-18 months ensures early protection of the individual, slows accumulation of susceptible young children and may correspond with other routine immunizations (for example, DTP booster). If first dose coverage is high (>90%) and school enrolment is high (>95%), giving the second dose at school entry may be an effective strategy for achieving high coverage and preventing outbreaks in schools.

- Combined vaccines (Measles and Rubella or Measles, Mumps and Rubella) may not be optimal for use in countries where vaccine coverage for measles vaccine of at least 80% cannot be achieved or maintained.

- Infants from 6 months of age should receive a dose of MCV in the following circumstances: (1) during a measles outbreak as part of intensified service delivery; (2) during SIAs in settings where risk of measles among infants remains high (e.g. in endemic countries experiencing regular outbreaks); (3) for internally displaced populations and refugees, and populations in conflict zones; (4) for individual children at high risk of contracting measles (e.g. contacts of known measles cases or in settings with increased risk of exposure during outbreaks such as day-care facilities); (5) for infants travelling to countries experiencing measles outbreaks; and (6) for infants known to be HIV-positive. This should be considered a supplementary dose and recorded on the child’s vaccination record as “MCV0”.

- Measles vaccination should be routinely administered to potentially susceptible, asymptomatic HIV-positive children and adults. In areas where there is a high incidence of both HIV infection and measles, MCV1 may be offered as early as age 6 months. Two additional doses of measles vaccine should be administered to these children according to the national immunization schedule.

- Mild, concurrent infections are not considered a contraindication to vaccination, but it should be avoided if the patient has a high fever or other signs of serious disease. Theoretically, measles vaccine - alone or in combination with other vaccines - should also be avoided by pregnant women. Furthermore, measles vaccination is contraindicated in people who are severely immunocompromised due to congenital disease; severe HIV infection; advanced leukaemia or lymphoma, etc.

## 9 Rubella


- All countries that have not yet introduced rubella vaccine, and are providing 2 doses of measles vaccine using routine immunization, or SIAs, or both, should consider including rubella containing vaccines (RCVs) in their immunization programme. Countries planning to introduce RCVs should review the epidemiology of rubella, including the susceptibility profile of the population; assess the burden of CRS; and establish rubella and CRS prevention as a public health priority.

- Because rubella is not as highly infectious as measles and because the effectiveness of 1 dose of an RCV is > 95% even at 9 months of age, only 1 dose of rubella vaccine is required to achieve rubella elimination if high coverage is achieved. However, when combined with measles vaccination, it may be easier to implement a second dose of RCV’s using the same combined MR vaccine or MMR vaccine for both doses.

- There are two general approaches to the use of rubella vaccine: (i) exclusive focus on reducing CRS by immunizing adolescent girls or women of childbearing age, or both groups, to provide individual protection; (ii) focus on interrupting transmission of rubella virus and eliminating rubella and CRS, by introducing rubella vaccination into the routine childhood immunization schedule combined with the vaccination of older age groups who are susceptible to rubella.

- To avoid the potential of an increased risk of CRS, countries should achieve and maintain immunization coverage of 80% or greater with at least 1 dose of an RCV delivered through routine services or regular campaigns, or both.

- The first dose of RCV can be delivered at 9 or 12 months depending on the measles vaccination schedule.

- RCV’s can be administered concurrently with inactivated vaccines. As a general rule, live vaccines should be given either simultaneously with RCV’s, or at least 4 weeks apart. An exception to this is oral polio vaccine, which can be given at any time before or after RCV’s without interfering in the response to either vaccine. Interference may occur between MMR and yellow fever vaccines if they are simultaneously administered to children < 2 years of age.

- Because of a theoretical, but never demonstrated, teratogenic risk rubella vaccination in pregnant women should be avoided in principle, and those planning a pregnancy are advised to avoid pregnancy for 1 month following vaccination.

- Administration of blood or blood products before or shortly after vaccination may interfere with vaccine efficacy. If only rubella vaccines persons who received blood products should wait at least 3 months before vaccination and, if possible, blood products should be avoided for up to 2 weeks postvaccination. Vaccinated persons are not eligible to donate blood for 1 month after vaccination.

## 10 Human Papillomavirus (HPV)


- Recommended target population for the prevention of cervical cancer: females aged 9–14 years, prior to becoming sexually active.
Table 2: Recommended Routine Immunization for Children (updated March 2017)

- 2-dose schedule with an interval of 6 months between doses is recommended for females younger than 15 years. Those females who are ≥15 years at the time of the second dose are also adequately protected by 2 doses.
- The immunization of multiple cohorts of girls aged 9–14 years is recommended when the vaccine is first introduced. If resources are available, the age range could be expanded up to 18 years.
- If the interval between doses is shorter than 5 months, then a third dose should be given at least 6 months after the first dose.

A 3-dose schedule (0, 1–2, 6 months) is recommended for females aged 15 years and older, and for those know to be immunocompromised and/or HIV-infected (regardless of whether they are receiving antiretroviral therapy). It is not necessary to screen for HPV infection or HIV infection prior to HPV vaccination.

These schedule recommendations apply to the bivalent, quadrivalent, and nonavalent vaccines. Both HPV vaccines can be co-administered with other live and non-live vaccines using separate syringes and different injection sites.

Data on the safety of HPV vaccination in pregnancy are limited, and HPV vaccination of pregnant women should be avoided.

HPV vaccines should be introduced as part of a coordinated strategy to prevent cervical cancer.

HPV vaccination of males is not recommended as a priority, especially in resource-constrained settings, as the available evidence indicates that the first priority should be for cervical cancer prevention. HPV vaccines should be introduced as part of a coordinated strategy to prevent cervical cancer.

HPV vaccines are contraindicated in immunocompromised persons including HIV-infected individuals, but the immune response may be lower than in fully immunocompetent persons. Inactivated Vero cell-derived vaccines should be used preferentially over live attenuated or live recombinant vaccines in immunocompromised persons. HIV testing is not a prerequisite for vaccination.

If the JE risk is sufficient to warrant vaccination of pregnant women, inactivated Vero cell-derived vaccines should be used preferentially over live attenuated or live recombinant vaccines based on the general precautionary principle against using live vaccines in pregnant women especially if alternative types of vaccines are available. Pregnancy testing is not a prerequisite for JE vaccination. Inadvertent administration of live attenuated or live recombinant JE vaccine to a pregnant woman is not an indication for termination of the pregnancy.

Yellow Fever

- WHO recommends that all endemic countries should introduce YF vaccine into their routine immunization programmes.
- A single dose of YF vaccine is sufficient to confer sustained lifelong protective immunity against YF disease; a booster dose is not necessary.
- It is recommended that YF vaccine be given to children at age 9-12 months at the same time as the measles vaccine.
- The vaccine is contraindicated in children aged <6 months and is not recommended for those aged 6-8 months, except during epidemics when the risk of infection with the YF virus is very high. Other contraindications for YF vaccination are severe hyper-sensitivity to egg antigens and severe immunodeficiency.
- Preventive mass vaccination campaigns are recommended for inhabitants of areas at risk of YF where there is low vaccination coverage. Vaccination should be provided to everyone aged ≥ 9 months, in any area with reported cases. Noting that YF is a live vaccine, a risk-benefit assessment should be undertaken for all pregnant and lactating women.
- Vaccine should be offered to all unvaccinated travelers aged ≥ 9 months, travelling to and from at-risk areas, unless they belong to the group of individuals for whom YF vaccination is contraindicated.
- YF vaccine may be administered simultaneously with other vaccines.

Japanese Encephalitis (JE)

- JE vaccination should be integrated into national immunization schedules in all areas where JE is recognized as a public health priority.
- The most effective immunization strategy in JE endemic settings is a one-time campaign in the primary target population, as defined by local epidemiology (typically children aged <15 years), followed by incorporation of JE vaccine into the routine childhood immunization programme.
- The following vaccine dosing schedules and age of administration are recommended. The need for a booster dose in endemic settings has not been clearly established for any of the vaccines listed below:
  - Inactivated Vero cell-derived vaccine: Primary series according to manufacturer’s recommendations (these vary by product), generally 2 doses at 4- to 6-week intervals starting the primary series at ≥6 months of age in endemic settings
  - Live attenuated vaccine: Single dose administered at ≥6 months of age
  - Live recombinant vaccine: Single dose administered at ≥9 months of age
- Preferably, inactivated mouse brain-derived vaccines should be replaced by the newer generation JE vaccines discussed in this position paper. Inactivated mouse brain-derived vaccines may continue to play a role in combatting JE in some countries, but overall these products have a less favourable safety profile due to their increased reactogenicity compared to newer JE vaccines. Other disadvantages include the variability of manufacturing, the cost, the higher number of doses required and the need for boosters.
- Despite a lack of comprehensive immunogenicity/effectiveness and safety data for all possible combinations of JE and other routine vaccines, co-administration for programmatic reasons seems acceptable, even in the context of mass campaigns.
- Inactivated JE vaccine can be used in immunocompromised persons including HIV-infected individuals, but the immune response may be lower than in fully immunocompetent persons.
- A single dose of YF vaccine is sufficient to confer sustained lifelong protective immunity against YF disease; a booster dose is not necessary.
- Vaccine should be offered to all unvaccinated travelers aged ≥ 9 months, travelling to and from at-risk areas, unless they belong to the group of individuals for whom YF vaccination is contraindicated.
- YF vaccine may be administered simultaneously with other vaccines.

Tick-Borne Encephalitis (TBE)

- Since the incidence of tick-borne encephalitis may vary considerably between and even within geographical regions, public immunization strategies should be based on risk assessments conducted at country, regional or district level, and they should be appropriate to the local endemic situation. Therefore, establishing case reporting of the disease is essential before deciding on the most appropriate preventive measures to be taken.
- In areas where the disease is highly endemic (that is, where the average prevaccination incidence of clinical disease is ≥5 cases/100,000 population per year), implying that there is a high individual risk of infection, WHO recommends that vaccination be offered to all age groups, including children.
- Because the disease tends to be more serious in individuals aged >50–60 years this age group constitutes an important target for immunization.
- Where the prevaccination incidence of the disease is moderate or low (that is, the annual average during a 5-year period is <5/100,000) or is limited to particular geographical locations or certain outdoor activities, immunization should target individuals in the most severely affected cohorts.
- People travelling from non-endemic areas to endemic areas should be offered vaccination if their visits will include extensive outdoor activities.
Vaccination against the disease requires a primary series of 3 doses; those who will continue to be at risk should probably have ≥1 booster doses. Within the considerable range of acceptable dose intervals, the relevant national authorities should select the most rational primary schedule for their national, regional or district immunization programmes. Although there is a strong indication that the spacing of boosters could be expanded considerably from the intervals currently recommended by the manufacturers (every 3-5 years), the evidence is still insufficient for a definitive recommendation on the optimal frequency and number of booster doses. Countries should therefore continue to recommend the use of vaccines in accordance with local disease epidemiology and current schedules until more definitive information becomes available.

For the vaccines manufactured in Austria and Germany (FSME-Immun and Encepur;) that can be given starting from > 1 year of age an interval of 1–3 months is recommended between the first 2 doses, and 5–12 months between the second and third doses. When rapid protection is required, for example for people who will be travelling to endemic areas, the interval between the first 2 doses may be reduced to 1–2 weeks. With the vaccines manufactured in the Russian Federation (TBE-Moscow and EnceVir) the recommended intervals are 1–7 months between the first 2 doses, and 12 months between the second and third doses. Booster doses are recommended every 3 years for those at continued risk of exposure. The currently recommended booster interval should be maintained until more data have been obtained on the duration of protection induced by the Russian vaccines. Regardless of the duration of the delay, interrupted schedules should be resumed without repeating previous doses.

Position paper reference: Weekly Epid. Record (2008, 83: 49-59) [pdf 297kb] Recommended for school-age and/or preschool-age children in areas where typhoid fever in these age groups is shown to be a significant public health problem, particularly where antibiotic-resistant S. Typhi is prevalent.

Vaccine options - Vi polysaccharide typhoid vaccine requires one parenterally administered dose which may be given after the age of 2 years; the liquid form of Ty21a live oral vaccine (for use in individuals from the age of 2 years) is no longer available; the capsule form of Ty21a (for use in individuals from the age of 5 years) requires 3 or 4 orally administered doses. See position paper for further details.

Booster - In most endemic settings, a booster dose of the concerned vaccine 3 to 7 years after the primary immunization seems appropriate.

Position paper reference: Weekly Epid. Record (2010, 85, 117-128) [pdf 283kb] In cholera-endemic countries, vaccinating the entire population is not warranted. Rather, vaccination should be targeted at high-risk areas and population groups. The primary targets for cholera vaccination in many endemic areas are preschool-aged and school aged children. Other groups that are especially vulnerable to severe disease and for which the vaccines are not contraindicated may also be targeted, such as pregnant women and HIV-infected individuals. Consider vaccinating older age groups if funding is available.

Two types of oral cholera vaccines are available: (i) Dukoral (WC-rBS) and (ii) Sanchol and mORCVAX. The live attenuated single-dose vaccine (CVD 103-Hgr) is no longer produced. The injectable vaccine is still manufactured in a few countries but its use is not recommended mainly because of its limited efficacy and short duration of protection.

Dukoral is not licensed for children < 2 years. Children aged 2-5 years should receive 3 doses ≥7 days apart (but not more than 6 weeks). Intake of food and drink should be avoided for 1 hour before and after vaccination. If the interval between doses is delayed >6 weeks, primary vaccination should be restarted. One booster dose is recommended every 6 months, and if the interval between primary immunization, and the booster is >6 months, primary immunization must be restarted.

Adults and children ≥6 years should receive 2 doses of Dukoral ≥7 days apart (but not more than 6 weeks). Intake of food and drink should be avoided for 1 hour before and after vaccination. If the interval between doses is delayed >6 weeks, primary vaccination should be restarted. A booster dose every 2 years is recommended. If the interval between the primary series and booster immunization is > 2 years, primary immunization must be repeated.

Shanchol and mORCVAX: two liquid doses orally 14 days apart for individuals ≥1 year. A booster dose is recommended after 2 years.

16 Meningococcal


Both conjugate and polysaccharide vaccines are efficacious and safe when used in pregnant women.

MenA conjugate vaccine (5ug) a 1-dose schedule is recommended at 9-18 months of age based on local programmatic and epidemiologic considerations. The vaccine should be administered by deep intramuscular injection, preferably in the anterolateral aspect of the thigh. There is no reason to expect interference when co-administered with other vaccines. The need for a booster dose has not been established.

If in a specific context there is a compelling reason to vaccinate infants younger than 9 months, a 2-dose schedule should be used starting at 3 months of age, with an interval of at least 8 weeks between doses.

For monovalent MenC conjugate vaccine one single intramuscular dose is recommended for children aged >12 months, teenagers and adults. Children 2-11 months require 2 doses administered at an interval of at least 2 months and a booster about 1 year after. If the primary series is interrupted, vaccination should be resumed without repeating the previous dose.

Quadrivalent conjugate vaccines (A,C,W135,Y-D and A,C,W135,Y-CRM) should be administered as one single intramuscular dose to individuals ≥ 2 years. A,C,W135,Y-D is also licensed for children 9-23 months of age, and given as a 2-dose series, 3 months apart beginning at age 9 months. If the primary series is interrupted, vaccination should be resumed without repeating the previous dose.

Meningococcal polysaccharide vaccines are less, or not, immunogenic in children under 2 years of age.

Meningococcal polysaccharide vaccines can be used for those > 2 years of age to control outbreaks in countries where limited economic resources or insufficient supply restrict the use of meningococcal conjugate vaccines. Polysaccharide vaccines should be administered to individuals ≥2 years old as one single dose. One booster 3-5 years after the primary dose may be given to persons considered to be a continued high risk of exposure, including some health workers. See position paper for details.
Table 2: Recommended Routine Immunization for Children (updated March 2017)

18 Rabies

- Production and use of nerve-tissue rabies vaccines should be discontinued and replaced with cell-culture-based vaccines (CCVs).
- Recommended for anyone who will be at continual, frequent or increased risk of exposure to the rabies virus, either as a result of their residence or occupation. Travellers with extensive outdoor exposure in rural high-risk areas where immediate access to appropriate medical care may be limited should also be vaccinated regardless of the duration of stay. Where canine rabies is a public health problem, WHO encourages studies on the feasibility, cost-effectiveness, and long-term impact of incorporating rabies vaccination into the immunization programme for infants and children.
- The series is given by intramuscular or intradermal injection at 0, 7 and 21 or 28 days.
- Intramuscular administration: For adults and children aged ≥2 years, the vaccine should always be administered in the deltoid area of the arm; for children aged < 2 years, the anterolateral area of the thigh is recommended. Rabies vaccine should not be administered in the gluteal area, as the induction of an adequate immune response may be less reliable.
- Booster doses of rabies vaccines are not required for individuals living in or travelling to high-risk areas who have received a complete primary series of pre-exposure or post-exposure prophylaxis with a cell-culture-based rabies vaccine (CCV).
- Periodic booster injections are recommended only for people whose occupation puts them at continual or frequent risk of exposure. If available, antibody monitoring is preferred to the administration of routine boosters.
- Because vaccine-induced immunity persists in most cases for years, a booster is recommended only if rabies-virus neutralizing antibody titres fall to <0.5 IU/ml.
- Antibody testing should be done every 6 months for people at risk of laboratory exposure to high concentrations of live rabies virus, and every 2 years for professionals who are not at continual risk of exposure through their activities, such as certain categories of veterinarians and animal health officers.

19 Dengue (CYD-TDV)

- Countries should consider introduction of the dengue vaccine CYD-TDV only in geographic settings (national or subnational) where epidemiological data indicate a high burden of disease.
- In defining populations to be targeted for vaccination, prior infection with dengue virus of any serotype, as measured by seroprevalence, should be approximately 70% or greater in the age group targeted for vaccination in order to maximize public health impact and cost-effectiveness.
- Vaccination of populations with seroprevalence between 50% and 70% is acceptable but the impact of the vaccination programme may be lower.
- The vaccine is not recommended when seroprevalence is below 50% in the age group targeted for vaccination.
- Dengue vaccine introduction should be a part of a comprehensive dengue control strategy, including well executed and sustained vector control, evidence-based best practices for clinical care for all patients with dengue illness, and strong dengue surveillance. Vaccine introduction must be accompanied by a targeted communication strategy.
- Decisions about introduction require careful assessment at the country level, including consideration of local priorities, national and subnational dengue epidemiology, predicted impact and cost-effectiveness with country-specific inputs, affordability and budget impact.
- At the time of introduction, countries are encouraged to have a functional pharmacovigilance system with at least minimal capacity to monitor and manage adverse events following immunization.
- Countries considering vaccination should also have a dengue surveillance system able to detect and report hospitalized and severe dengue cases consistently over time.
- Administered as a 3-dose series given on a 0/6/12 month schedule. If a vaccine dose is delayed for any reason, the vaccine course should be resumed (not restarted), maintaining the 6-month interval between subsequent doses. Because of the 12-month duration of the immunization schedule and to enable better vaccine monitoring, countries should have systems in place for tracking vaccination.
- Because of the association of CYD-TDV with increased risk of hospitalized and severe dengue illness in the 2–5 year age group, CYD-TDV is not recommended for use in children under 9 years of age.
- The target age for routine vaccination should be defined by each country, based on maximizing vaccination impact and programmatic feasibility of targeting specific age groups.
- Some countries may experience the highest incidence of dengue illness among adults and may consider vaccinating populations up to 45 years of age.
- Catch-up campaigns targeting older age groups may be considered if additional impact is
desired and the additional costs can be met.

- Co-administration is permissible with live and other non-live attenuated vaccines. Co-administration may be desirable to reduce programmatic costs associated with school-based vaccination programmes.

- CYD-TDV is not recommended for pregnant and lactating women due to lack of sufficient data in this population. However, the limited data collected during the clinical trials on inadvertent immunization of pregnant women have yielded no evidence of harm to the fetus or pregnant woman. Women of child-bearing age who are targeted for vaccination do not need to be tested for pregnancy.

- Until data become available, there is no recommendation for the use of CYD-TDV in HIV-infected or immunocompromised individuals.

- There is no recommendation for vaccination of travellers or health-care workers at this time.

20 Mumps


- Recommended for use in high performing immunization programmes with the capacity to maintain coverage over 80% and where mumps reduction is a public health priority.

- If implemented, a combination vaccine of measles, mumps and rubella is recommended.

21 Seasonal Influenza (Inactivated Vaccine)


- For countries considering the initiation or expansion of programmes for seasonal influenza vaccination, WHO recommends that pregnant women should have the highest priority. Children aged < 6 months are not eligible to receive currently licensed influenza vaccines and should be protected against influenza through vaccination of their mothers during pregnancy and through ensuring vaccination of close contacts.

- Additional risk groups to be considered are children aged 6-59 months, elderly persons ≥ 65 years of age, individuals with specific chronic medical conditions, and health-care workers. Countries with existing influenza vaccination programmes targeting any of these additional groups should continue to do so and should incorporate immunization of pregnant women into such programmes.

- A single dose is appropriate for those ≥ 9 years of age, including pregnant women. Inactivated influenza vaccine is safe to give throughout pregnancy.

- Children aged 6-59 months should receive 2 doses at least 4 weeks apart. Children aged 6-35 months should receive a pediatric dosage.

- Annual vaccination (or re-vaccination, if the vaccine strains are identical) is recommended. Previously vaccinated children 6-59 months require only one-dose.

22 Varicella


- Countries where varicella is an important public health burden could consider introducing varicella vaccination in the routine childhood immunization programme. However, resources should be sufficient to ensure reaching and sustaining vaccine coverage ≥ 80%. Decision-making on childhood varicella vaccination should also include consideration of the possible impact on herpes zoster.

- Depending on the goal of the vaccination programme, 1-2 doses should be given with the first dose administered at 12-18 months of age. The minimum interval between doses should be as recommended by the manufacturer, ranging from 4 weeks to 3 months.

- Countries with a high average age (≥ 15 years) of acquisition of infection could consider alternative vaccination strategies such as vaccination of adolescents and adults without evidence of varicella immunity. This strategy requires a 2-dose schedule.

- Varicella vaccination is contraindicated during pregnancy and pregnancy should be delayed for 4 weeks after vaccination. Termination of pregnancy is not indicated if vaccination was carried out inadvertently during pregnancy.

- Varicella vaccine can be administered concomitantly with other vaccines. Unless given together with other live viral vaccines (measles, MR, MMR), it should be administered at a minimum interval of 28 days.

- Countries should consider vaccination of potentially susceptible health-care workers (i.e. unvaccinated and with no history of varicella) with 2 doses of varicella vaccine.